Ovarian cancer: immunotherapy may boost survival benefit of later chemotherapy

  • Gynecol Oncol
  • 14 Aug 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Postimmunotherapy treatments yield favorable survival benefit in women with heavily pretreated ovarian cancer, including those who did not derive benefit from immune checkpoint inhibitors.
  • Taxane- and platinum-based therapies were the most common subsequent treatments.

Why this matters

  • Findings suggest immunotherapy improves efficacy of subsequent chemotherapy.

Study design

  • 79 patients with recurrent ovarian cancer (median age, 57 years) who received ≥1 subsequent treatment after immune checkpoint inhibitors.
  • Funding: MSK Cancer Center.

Key results

  • 84% of patients had platinum-resistant ovarian cancer.
  • Median time from diagnosis to immune checkpoint inhibitor initiation was 39.7 months and median number of treatment lines was 4.
  • 20% of patients derived benefit from checkpoint inhibitors.
  • Most common subsequent treatments (any line) were taxane (53%), platinum-based therapy (47%), pegylated liposomal doxorubicin (30%), and gemcitabine (22%).
  • 59% of patients received bevacizumab.
  • Median follow-up was 18.3 months postimmune checkpoint inhibitors and median OS was 18.3 (95% CI, 11.8-22.7) months.
  • OS was not significantly different in patients who derived benefit from immune checkpoint inhibitors vs those who did not (aHR, 0.55; P=.19).

Limitations

  • Retrospective design.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit